Strides gains USFDA approval for Theophylline Extended-Release Tablets, 300 mg and 450 mg

Strides Pharma Science's subsidiary, Strides Pharma Global Singapore, received USFDA approval for generic Theophylline Extended-Release Tablets, 300 mg and 450 mg, bioequivalent to Schering Corp's THEO-DUR. Indicated for chronic asthma and lung diseases, the tablets will be manufactured in Bengaluru, with a market size of ~$11.5 million.